

Aaron David Schimmer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9107315/aaron-david-schimmer-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261
papers

11,995
citations

56
h-index

101
g-index

274
ext. papers

13,835
ext. citations

6.3
avg, IF

6.12
L-index

#	Paper	IF	Citations
261	Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux.. <i>Communications Biology</i> , 2022 , 5, 132	6.7	0
260	Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 51	21	5
259	Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations.. <i>JACC: CardioOncology</i> , 2022 , 4, 38-49	3.8	0
258	Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. <i>Haematologica</i> , 2021 , 106, 56-63	6.6	11
257	Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial. <i>Blood</i> , 2021 , 138, 1263-1263	2.2	0
256	Serine and Threonine Phosphorylation Marks Proteins for Degradation By Clpxp. <i>Blood</i> , 2021 , 138, 3329-3329		
255	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1908-1918	4.4	2
254	A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity. <i>JCI Insight</i> , 2021 , 6,	9.9	7
253	Mitochondrial ATP-Dependent Proteases-Biological Function and Potential Anti-Cancer Targets. <i>Cancers</i> , 2021 , 13,	6.6	2
252	Mammary epithelial cells have lineage-rooted metabolic identities. <i>Nature Metabolism</i> , 2021 , 3, 665-681	14.6	5
251	Very long chain fatty acid metabolism is required in acute myeloid leukemia. <i>Blood</i> , 2021 , 137, 3518-3532	2.2	15
250	Novel subtypes of -mutated AML with distinct outcome. <i>Molecular and Cellular Oncology</i> , 2021 , 8, 1924600	6.0	0
249	Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia. <i>Haematologica</i> , 2021 , 106, 574-579	6.6	1
248	E1 Enzymes as Therapeutic Targets in Cancer. <i>Pharmacological Reviews</i> , 2021 , 73, 1-58	22.5	20
247	Mitochondrial and Metabolic Pathways Regulate Nuclear Gene Expression to Control Differentiation, Stem Cell Function, and Immune Response in Leukemia. <i>Cancer Discovery</i> , 2021 , 11, 1052-1066	24.4	2
246	Biological and therapeutic implications of a unique subtype of NPM1 mutated AML. <i>Nature Communications</i> , 2021 , 12, 1054	17.4	7
245	Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. <i>Blood</i> , 2021 , 138, 234-245	2.2	22

244	Transduction of Primary AML Cells with Lentiviral Vector for Study or Engraftment. <i>STAR Protocols</i> , 2020 , 1, 100163	1.4	
243	Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal. <i>Cell Stem Cell</i> , 2020 , 26, 926-937.e10	18	16
242	Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. <i>British Journal of Haematology</i> , 2020 , 191, 748-754	4.5	9
241	The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	22
240	Screening for Dental Infections Achieves 6-Fold Reduction in Dental Emergencies During Induction Chemotherapy for Acute Myeloid Leukemia. <i>JCO Oncology Practice</i> , 2020 , 16, e1397-e1405	2.3	1
239	Targeting nuclear import and export in hematological malignancies. <i>Leukemia</i> , 2020 , 34, 2875-2886	10.7	14
238	Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. <i>Blood</i> , 2020 , 136, 35-36	2.2	
237	Leukemia Stem Cells Demonstrate Increased DNA Damage Repair and Chemoresistance in Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 2-2	2.2	
236	Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation. <i>Blood</i> , 2020 , 136, 8-9	2.2	
235	IPO11 Regulates the Nuclear Import of BZW1/2 and Is Necessary for AML Cells and Stem Cells. <i>Blood</i> , 2020 , 136, 22-23	2.2	
234	CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. <i>Blood</i> , 2020 , 136, 6-7	2.2	0
233	The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness. <i>Blood</i> , 2020 , 136, 1-2	2.2	
232	Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS. <i>Blood</i> , 2020 , 136, 1-2	2.2	2
231	Mitochondrial carrier homolog 2 is necessary for AML survival. <i>Blood</i> , 2020 , 136, 81-92	2.2	8
230	COVID-19: a pandemic experience that illuminates potential reforms to health research. <i>EMBO Molecular Medicine</i> , 2020 , 12, e13278	12	3
229	Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. <i>Current Oncology</i> , 2020 , 28, 128-137	2.8	0
228	Targeting neurolysin in acute myeloid leukemia. <i>Molecular and Cellular Oncology</i> , 2020 , 7, 1761243	1.2	2
227	Mitochondrial ClpP serine protease-biological function and emerging target for cancer therapy. <i>Cell Death and Disease</i> , 2020 , 11, 841	9.8	18

226	The role of mitochondrial proteases in leukemic cells and leukemic stem cells. <i>Stem Cells Translational Medicine</i> , 2020 , 9, 1481-1487	6.9	4
225	Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. <i>Molecular Oncology</i> , 2020 , 14, 2533-2545	7.9	6
224	Mitochondria regulate AML differentiation independent of oxidative phosphorylation and metabolism. <i>Molecular and Cellular Oncology</i> , 2020 , 7, 1815503	1.2	
223	Emotion And Symptom-focused Engagement (EASE): a randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia. <i>Supportive Care in Cancer</i> , 2020 , 28, 163-176	3.9	13
222	De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 6377-6390	8.3	19
221	Tafazzin modulates cellular phospholipid composition to regulate AML stemness. <i>Molecular and Cellular Oncology</i> , 2019 , 6, e1620051	1.2	1
220	17-Hydroxy Wortmannin Restores TRAIL ^o Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1265-1277 ¹	6.1	1
219	Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. <i>Cancer Cell</i> , 2019 , 35, 721-737.e9	24.3	108
218	Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review. <i>JAMA Cardiology</i> , 2019 , 4, 380-387	16.2	24
217	Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity. <i>Acta Neuropathologica</i> , 2019 , 137, 939-960	14.3	39
216	The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids. <i>Cell Stem Cell</i> , 2019 , 24, 621-636.e16	18	19
215	Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. <i>Leukemia</i> , 2019 , 33, 37-51	10.7	34
214	Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	68
213	Global Interactome Mapping of Mitochondrial Intermembrane Space Proteases Identifies a Novel Function for HTRA2. <i>Proteomics</i> , 2019 , 19, e1900139	4.8	9
212	IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells. <i>Blood</i> , 2019 , 134, 2530-2530	2.2	1
211	Phospholipid metabolism regulates AML growth and stemness. <i>Aging</i> , 2019 , 11, 3895-3897	5.6	3
210	Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. <i>Blood Advances</i> , 2019 , 3, 2307-2311	7.8	7
209	The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia. <i>Haematologica</i> , 2019 , 104, 963-972	6.6	9

208	A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. <i>Supportive Care in Cancer</i> , 2019 , 27, 2295-2300	3.9	3
207	The experience of medical communication in adults with acute leukemia: Impact of age and attachment security. <i>Psycho-Oncology</i> , 2019 , 28, 122-130	3.9	4
206	Pain in patients with newly diagnosed or relapsed acute leukemia. <i>Supportive Care in Cancer</i> , 2019 , 27, 2789-2797	3.9	4
205	AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. <i>Leukemia Research</i> , 2018 , 68, 22-28	2.7	6
204	Prevalence of oral lesions in and dental needs of patients with newly diagnosed acute leukemia. <i>Journal of the American Dental Association</i> , 2018 , 149, 470-480	1.9	7
203	The importance of meaningful activity in people living with acute myeloid leukemia. <i>Leukemia Research</i> , 2018 , 67, 86-91	2.7	5
202	Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived. <i>Leukemia and Lymphoma</i> , 2018 , 59, 237-240	1.9	1
201	Traumatic stress in patients with acute leukemia: A prospective cohort study. <i>Psycho-Oncology</i> , 2018 , 27, 515-523	3.9	18
200	Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. <i>HemaSphere</i> , 2018 , 2, e44	0.3	8
199	A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 1350-1350	2.2	1
198	Metabolic Flexibility in Leukemia-Adapt or Die. <i>Cancer Cell</i> , 2018 , 34, 695-696	24.3	3
197	MTCH2-mediated mitochondrial fusion drives exit from naïve pluripotency in embryonic stem cells. <i>Nature Communications</i> , 2018 , 9, 5132	17.4	34
196	Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia. <i>Chemotherapy</i> , 2018 , 63, 225-237	3.2	2
195	The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. <i>Blood Advances</i> , 2018 , 2, 2658-2671	7.8	30
194	Mitochondrial Shapeshifting Impacts AML Stemness and Differentiation. <i>Cell Stem Cell</i> , 2018 , 23, 3-4	18	1
193	Acyldepsipeptide Analogs Dysregulate Human Mitochondrial ClpP Protease Activity and Cause Apoptotic Cell Death. <i>Cell Chemical Biology</i> , 2018 , 25, 1017-1030.e9	8.2	42
192	Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes. <i>Leukemia Research</i> , 2017 , 59, 93-96	2.7	3
191	Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 215-219	2	3

190	Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. <i>Blood</i> , 2017 , 129, 2657-2666	2.2	43
189	Emerging therapies for acute myeloid leukemia: translating biology into the clinic. <i>JCI Insight</i> , 2017 , 2,	9.9	21
188	Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. <i>Leukemia Research</i> , 2017 , 61, 39-43	2.7	2
187	Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 774-781	2	3
186	Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells. <i>Cancer Discovery</i> , 2017 , 7, 670-672	24.4	5
185	Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis. <i>Hematological Oncology</i> , 2017 , 35, 810-813	1.3	1
184	Characterizing the mitochondrial DNA polymerase gamma interactome by BioID identifies Ruvbl2 localizes to the mitochondria. <i>Mitochondrion</i> , 2017 , 32, 31-35	4.9	10
183	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. <i>Blood Advances</i> , 2017 , 1, 1729-1738	7.8	34
182	Emotion and Symptom-focused Engagement (EASE): A randomized pilot trial of an integrated psychosocial and palliative care intervention for individuals with acute leukemia (AL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7041-7041	2.2	3
181	A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. <i>Investigational New Drugs</i> , 2016 , 34, 614-243	4.3	18
180	Mitochondrial DNA repair and replication proteins revealed by targeted chemical probes. <i>Nature Chemical Biology</i> , 2016 , 12, 567-73	11.7	62
179	Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2432-6	1.9	1
178	Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells. <i>Applied Radiation and Isotopes</i> , 2016 , 110, 1-7	1.7	10
177	RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3739-3757	15.9	65
176	A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations. <i>Blood</i> , 2016 , 128, 1073-1073	2.2	41
175	A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. <i>Oncotarget</i> , 2016 , 7, 49777-49785	3.3	13
174	Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism. <i>Oncotarget</i> , 2016 , 7, 2765-79	3.3	18
173	Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. <i>Oncotarget</i> , 2016 , 7, 79722-79735	3.3	98

172	Depression and hopelessness in patients with acute leukemia: the psychological impact of an acute and life-threatening disorder. <i>Psycho-Oncology</i> , 2016 , 25, 979-89	3.9	32
171	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy. <i>American Journal of Hematology</i> , 2016 , 91, 283-6	7.1	31
170	Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells. <i>Haematologica</i> , 2016 , 101, e449-e453	6.6	4
169	A 17-gene stemness score for rapid determination of risk in acute leukaemia. <i>Nature</i> , 2016 , 540, 433-437	50.4	369
168	A phase I study of elesclomol sodium in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2437-40	1.9	23
167	The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. <i>Blood</i> , 2016 , 127, 1676-86	2.2	36
166	A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. <i>Cancer Medicine</i> , 2016 , 5, 3031-3040	4.8	34
165	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2793-802	1.9	24
164	Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. <i>Cancer Research</i> , 2015 , 75, 2478-88	10.1	94
163	Drug discovery in academia. <i>Experimental Hematology</i> , 2015 , 43, 713-7	3.1	8
162	Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015 , 20, 1099-108	5.4	25
161	Mitochondrial DNA damage by bleomycin induces AML cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015 , 20, 811-20	5.4	12
160	Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015 , 20, 948-59	5.4	15
159	A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. <i>British Journal of Haematology</i> , 2015 , 168, 384-94	4.5	22
158	AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. <i>Blood</i> , 2015 , 125, 2120-30	2.2	148
157	Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin. <i>Haematologica</i> , 2015 , 100, e406-8	6.6	5
156	Targeting mitochondrial RNA polymerase in acute myeloid leukemia. <i>Oncotarget</i> , 2015 , 6, 37216-28	3.3	17
155	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2015 , 27, 864-76	24.3	191

154	Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity. <i>ACS Chemical Biology</i> , 2015 , 10, 2007-15	4.9	52
153	Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e151-6	2	10
152	The Canadian Choosing Wisely campaign: the Canadian Hematology Society's top five tests and treatments. <i>Annals of Hematology</i> , 2015 , 94, 541-5	3	13
151	Mapping the cellular response to small molecules using chemogenomic fitness signatures. <i>Science</i> , 2014 , 344, 208-11	33.3	174
150	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. <i>Nature</i> , 2014 , 506, 328-33	50.4	1011
149	Salvage induction chemotherapy after azacitidine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2014 , 166, 303-6	4.5	1
148	Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. <i>Cancer Research</i> , 2014 , 74, 4772-82	10.1	41
147	Finding new bearings: a qualitative study on the transition from inpatient to ambulatory care of patients with acute myeloid leukemia. <i>Supportive Care in Cancer</i> , 2014 , 22, 2435-43	3.9	16
146	Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen. <i>Leukemia Research</i> , 2014 , 38, 532-6	2.7	3
145	Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells. <i>PLoS ONE</i> , 2014 , 9, e93530	3.7	22
144	A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. <i>PLoS ONE</i> , 2014 , 9, e95281	3.7	21
143	A multicenter phase I/II study of obatoclox mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. <i>PLoS ONE</i> , 2014 , 9, e108694	3.7	58
142	Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. <i>Emerging Microbes and Infections</i> , 2014 , 3, e84	18.9	167
141	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. <i>American Journal of Hematology</i> , 2014 , 89, 363-8	7.1	57
140	Ibrutinib Sensitizes AML Cells to ROS Inducers Via a BTK-Independent Mechanism. <i>Blood</i> , 2014 , 124, 2226-2226	6	264
139	A porphodimethene chemical inhibitor of uroporphyrinogen decarboxylase. <i>PLoS ONE</i> , 2014 , 9, e89889	3.7	2
138	Traumatic stress symptoms in patients with acute leukemia (AL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9577-9577	2.2	
137	FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014 , 124, 5285-5285	2.2	

136	A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 5618-28	3.4	7
135	Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 7190-200	8.3	30
134	High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. <i>Leukemia Research</i> , 2013 , 37, 556-60	2.7	6
133	Symptom burden and supportive care in patients with acute leukemia. <i>Leukemia Research</i> , 2013 , 37, 731-67	4.7	88
132	Abducted by the illness: a qualitative study of traumatic stress in individuals with acute leukemia. <i>Leukemia Research</i> , 2013 , 37, 496-502	2.7	41
131	Boryl isocyanides enable facile preparation of bioactive boropeptides. <i>Angewandte Chemie - International Edition</i> , 2013 , 52, 8411-5	16.4	68
130	An evidence-based review of obatoclox mesylate in the treatment of hematological malignancies. <i>Core Evidence</i> , 2013 , 8, 15-26	4.9	54
129	Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. <i>British Journal of Haematology</i> , 2013 , 163, 458-64	4.5	21
128	Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. <i>Blood</i> , 2013 , 121, 2725-33	2.2	99
127	Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. <i>Haematologica</i> , 2013 , 98, 1896-904	6.6	46
126	The natural pesticide dihydrorotenone induces human plasma cell apoptosis by triggering endoplasmic reticulum stress and activating p38 signaling pathway. <i>PLoS ONE</i> , 2013 , 8, e69911	3.7	10
125	Traumatic stress in acute leukemia. <i>Psycho-Oncology</i> , 2013 , 22, 299-307	3.9	34
124	Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. <i>Journal of Clinical Investigation</i> , 2013 , 123, 315-28	15.9	91
123	Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells. <i>PLoS ONE</i> , 2013 , 8, e58367	3.7	28
122	Re-directing an alkylating agent to mitochondria alters drug target and cell death mechanism. <i>PLoS ONE</i> , 2013 , 8, e60253	3.7	31
121	Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. <i>PLoS ONE</i> , 2013 , 8, e74075	3.7	13
120	RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. <i>PLoS ONE</i> , 2013 , 8, e78641	3.7	52
119	Targeting the ubiquitin E1 as a novel anti-cancer strategy. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3201-9	3.3	15

118	Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. <i>Biochemical Pharmacology</i> , 2012 , 83, 207-17	6	61
117	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. <i>British Journal of Haematology</i> , 2012 , 158, 506-14	4.5	18
116	Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012 , 87, 323-6	7.1	14
115	Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents. <i>Medicinal Chemistry Research</i> , 2012 , 21, 2644-2651	2.2	23
114	Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. <i>Leukemia Research</i> , 2012 , 36, 1517-20	2.7	11
113	A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 330-6	2	28
112	Phosphopeptide selective coordination complexes as promising SRC homology 2 domain mimetics. <i>Inorganic Chemistry</i> , 2012 , 51, 8284-91	5.1	10
111	Drug Repositioning Efforts by Nonprofit Foundations 2012 , 389-431		
110	Suppression of cancer progression by MGAT1 shRNA knockdown. <i>PLoS ONE</i> , 2012 , 7, e43721	3.7	31
109	Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. <i>Cancer</i> , 2012 , 118, 6110-7	6.4	34
108	A genome wide shRNA screen identifies a hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2012 , 17, 666-78	5.4	20
107	Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. <i>PLoS ONE</i> , 2012 , 7, e30215	3.7	60
106	Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. <i>PLoS ONE</i> , 2012 , 7, e41102	3.7	22
105	Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 433-8	2	41
104	Clioquinol - a novel copper-dependent and independent proteasome inhibitor. <i>Current Cancer Drug Targets</i> , 2011 , 11, 325-31	2.8	33
103	A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. <i>Blood</i> , 2011 , 117, 1986-97	2.2	43
102	New sources of drugs for hematologic malignancies. <i>Blood</i> , 2011 , 117, 6747-55	2.2	33
101	Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 5605-9	2.9	51

100	Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. <i>Cancer Cell</i> , 2011 , 20, 674-88	24.3	425
99	Novel proteasome inhibitors to overcome bortezomib resistance. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1007-17	9.7	203
98	Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 1823-38	3.4	32
97	Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. <i>ChemMedChem</i> , 2011 , 6, 1459-70	3.7	44
96	Artificially Induced Protein-Membrane Anchorage with Cholesterol-Based Recognition Agents as a New Therapeutic Concept. <i>Angewandte Chemie</i> , 2011 , 123, 6372-6377	3.6	0
95	Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept. <i>Angewandte Chemie - International Edition</i> , 2011 , 50, 6248-53	16.4	14
94	Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. <i>Chemistry and Biology</i> , 2011 , 18, 445-53		80
93	Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity. <i>ACS Medicinal Chemistry Letters</i> , 2011 , 2, 577-82	4.3	30
92	Wnt inhibitor screen reveals iron dependence of β -catenin signaling in cancers. <i>Cancer Research</i> , 2011 , 71, 7628-39	10.1	95
91	Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. <i>Science Translational Medicine</i> , 2011 , 3, 67ra7	17.5	25
90	The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. <i>Molecular Pharmacology</i> , 2011 , 79, 672-80	4.3	47
89	Inhibition of SREBP1 sensitizes cells to death ligands. <i>Oncotarget</i> , 2011 , 2, 186-96	3.3	23
88	Targeting p53 Via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1836-1836	2.2	
87	Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 246-56	6.1	47
86	Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 61-5	1.9	16
85	Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. <i>Cancer Research</i> , 2010 , 70, 4949-60	10.1	35
84	Crystal structure of the human ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1 enzyme. <i>Journal of Biological Chemistry</i> , 2010 , 285, 20273-80	5.4	39
83	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 285-9	2	71

82	Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. <i>Chemical Communications</i> , 2010 , 46, 892-4	5.8	33
81	The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. <i>Blood</i> , 2010 , 115, 2251-9	2.2	122
80	The antihelminthic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. <i>Blood</i> , 2010 , 115, 4824-33	2.2	93
79	The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. <i>Blood</i> , 2010 , 116, 3593-603	2.2	79
78	Want fries with that? Antimyeloma drug combos. <i>Blood</i> , 2010 , 116, 510-1	2.2	
77	Effect of noncompetitive proteasome inhibition on bortezomib resistance. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1069-82	9.7	62
76	Clioquinol Arrests Cell Cycle at G1 Phase and Triggers Intrinsic Apoptosis In Myeloma and Leukemia Cells by Inhibiting Histone Deacetylases. <i>Blood</i> , 2010 , 116, 1836-1836	2.2	
75	Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. <i>Molecular Pharmacology</i> , 2009 , 76, 969-83	4.3	89
74	Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4741-6	2.2	106
73	Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. <i>Cancer Research</i> , 2009 , 69, 2739-47	10.1	81
72	Health care crisis in Gaza. <i>Cmaj</i> , 2009 , 180, 1230	3.5	
71	Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. <i>European Journal of Pharmaceutical Sciences</i> , 2009 , 36, 401-11	5.1	44
70	Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. <i>ChemBioChem</i> , 2009 , 10, 1959-64	3.8	74
69	SBDS-deficiency results in specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009 , 14, 77-89	5.4	20
68	Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. <i>British Journal of Haematology</i> , 2009 , 146, 76-85	4.5	114
67	Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. <i>Blood</i> , 2009 , 114, 3064-73	2.2	126
66	Identification of a potent natural triterpenoid inhibitor of proteasome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. <i>Blood</i> , 2009 , 113, 4027-37	2.2	82
65	Activation of Chloride Channels with the Anti-Parasitic Agent Ivermectin Induces Membrane Hyperpolarization and Cell Death in Leukemia Cells.. <i>Blood</i> , 2009 , 114, 410-410	2.2	1

64	Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. <i>British Journal of Haematology</i> , 2008 , 143, 738-43	4.5	21
63	The toxicology of Clioquinol. <i>Toxicology Letters</i> , 2008 , 182, 1-6	4.4	93
62	TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. <i>Biochemistry</i> , 2008 , 47, 6727-34	3.4	64
61	Apoptosis in leukemia: from molecular pathways to targeted therapies. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 5-11	4.2	25
60	Anoikis resistance and tumor metastasis. <i>Cancer Letters</i> , 2008 , 272, 177-85	9.9	392
59	Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008 , 70, 279-88	5.7	45
58	A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 8295-301	12.9	168
57	SBDS-deficient cells undergo accelerated apoptosis through the Fas-pathway. <i>Haematologica</i> , 2008 , 93, 363-71	6.6	43
56	Bcl-B expression in human epithelial and nonepithelial malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 3011-21	12.9	45
55	Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. <i>Cancer Research</i> , 2008 , 68, 6688-97	10.1	46
54	A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3546-55	6.1	130
53	Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3610-7	5.6	36
52	Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 339-41	1.9	3
51	Catalase activity and arsenic sensitivity in acute leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1976-81	1.9	17
50	Cyproheptadine displays preclinical activity in myeloma and leukemia. <i>Blood</i> , 2008 , 112, 760-9	2.2	42
49	Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. <i>BioTechniques</i> , 2008 , 44, ix-xiv	2.5	34
48	A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2008 , 13, 413-22	5.4	38
47	A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2008 , 13, 748-55	5.4	8

46	Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. <i>Cancer</i> , 2008 , 112, 1513-21	6.4	19
45	Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. <i>American Journal of Hematology</i> , 2008 , 83, 54-8	7.1	22
44	Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. <i>Leukemia Research</i> , 2008 , 32, 1480-2	2.7	11
43	Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1750-64	15.9	42
42	Chemical biology--understanding biology and advancing therapy. <i>Clinical and Investigative Medicine</i> , 2008 , 31, E282-9	0.9	1
41	Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). <i>Leukemia and Lymphoma</i> , 2007 , 48, 65-71	1.9	30
40	Myelodysplastic syndromes: the complexity of stem-cell diseases. <i>Nature Reviews Cancer</i> , 2007 , 7, 118-29	1.3	271
39	Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia. <i>Current Treatment Options in Oncology</i> , 2007 , 8, 277-86	5.4	15
38	Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 24-30	6.1	68
37	Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 811-22	9.7	64
36	Acute promyelocytic leukemia in patients aged 70 years and over -- a single center experience of unselected patients. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1654-8	1.9	17
35	A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. <i>Cancer Research</i> , 2007 , 67, 8307-15	10.1	53
34	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. <i>Blood</i> , 2007 , 110, 4047-54	2.2	48
33	A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 908-908	2.2	4
32	Induction of apoptosis in lymphoid and myeloid leukemia. <i>Current Oncology Reports</i> , 2006 , 8, 430-6	6.3	5
31	Global profiles of gene expression induced by adrenocorticotropin in Y1 mouse adrenal cells. <i>Endocrinology</i> , 2006 , 147, 2357-67	4.8	38
30	Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 2234-40	6.1	51
29	Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. <i>Clinical Cancer Research</i> , 2006 , 12, 5557-69	12.9	74

28	Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. <i>Cancer Research</i> , 2006 , 66, 2367-75	10.1	64
27	Targeting XIAP for the treatment of malignancy. <i>Cell Death and Differentiation</i> , 2006 , 13, 179-88	12.7	249
26	Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acid. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006 , 11, 1463-71	5.4	48
25	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.. <i>Blood</i> , 2006 , 108, 2007-2007	2.2	2
24	A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2006 , 108, 2654-2654	2.2	8
23	Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 215-9	3.1	43
22	Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. <i>Blood</i> , 2005 , 105, 4043-50	2.2	115
21	Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005 , 10, 1285-94	5.4	5
20	Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. <i>Cancer Research</i> , 2005 , 65, 2378-86	10.1	192
19	Targeting the IAP Family of Caspase Inhibitors as an Emerging Therapeutic Strategy. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 215-219	3.1	7
18	Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. <i>Cancer Research</i> , 2004 , 64, 7183-90	10.1	393
17	Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. <i>Journal of Biological Chemistry</i> , 2004 , 279, 48168-76	5.4	65
16	Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. <i>Cancer Cell</i> , 2004 , 5, 25-35	24.3	383
15	Functional Assessment of the Mitochondrial Pathway of Caspase Activation in Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004 , 104, 2995-2995	2.2	
14	Silencing of Caspase 8 Expression in Leukemia Cells and Patient Samples.. <i>Blood</i> , 2004 , 104, 2050-2050	2.2	
13	The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1239-48	6.1	100
12	Bcl-2 and apoptosis in chronic lymphocytic leukemia. <i>Current Treatment Options in Oncology</i> , 2003 , 4, 211-8	5.4	51
11	Self-concept as a "BMT patient", illness intrusiveness, and engulfment in allogeneic bone marrow transplant recipients. <i>Journal of Psychosomatic Research</i> , 2003 , 55, 419-25	4.1	35

10	Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. <i>Cancer Research</i> , 2003 , 63, 1242-8	10.1	51
9	The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant. <i>Supportive Care in Cancer</i> , 2002 , 10, 247-52	3.9	5
8	Dysregulation of apoptosis genes in hematopoietic malignancies. <i>Oncogene</i> , 2002 , 21, 3459-74	9.2	134
7	The triterpenoid CDDO induces apoptosis in refractory CLL B cells. <i>Blood</i> , 2002 , 100, 2965-72	2.2	146
6	Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. <i>Blood</i> , 2001 , 98, 3541-53	2.2	110
5	Illness intrusiveness among survivors of autologous blood and marrow transplantation. <i>Cancer</i> , 2001 , 92, 3147-54	6.4	36
4	Male sexual function after autologous blood or marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 279-83	4.7	22
3	BAD induces apoptosis in cells over-expressing Bcl-2 or Bcl-xL without loss of mitochondrial membrane potential. <i>Leukemia and Lymphoma</i> , 2001 , 42, 429-43	1.9	12
2	Osteoporosis after blood and marrow transplantation: clinical aspects. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 175-81	4.7	55
1	Phorbol ester impairs melanotropin receptor function and stimulates growth of cultured M2R melanoma cells. <i>European Journal of Pharmacology</i> , 1989 , 172, 29-39		5